Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide by Wilson, Rona et al.
BioMed CentralBMC Neuroscience
ssOpen AcceResearch article
Squalestatin alters the intracellular trafficking of a neurotoxic prion 
peptide
Rona Wilson1, Clive Bate2, Ronald Boshuizen3, Alun Williams2 and 
James Brewer*4
Address: 1Division of Immunology, Infection and Inflammation, Western Infirmary, University of Glasgow, G11 6NT, Glasgow, 2Department of 
Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, AL9 7TA, Herts, 3Pepscan systems B.V, Edelhertweg 
15, 8219 PH, Lelystad, The Netherlands and 4Centre for Biophotonics, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, G4 
ONR, Glasgow
Email: Rona Wilson - rkw1m@clinmed.gla.ac.uk; Clive Bate - cbate@rvc.ac.uk; Ronald Boshuizen - Ronald.Boshuizen@wur.nl; 
Alun Williams - alunwilliams@RVC.AC.UK; James Brewer* - james.brewer@strath.ac.uk
* Corresponding author    
Abstract
Background: Neurotoxic peptides derived from the protease-resistant core of the prion protein
are used to model the pathogenesis of prion diseases. The current study characterised the
ingestion, internalization and intracellular trafficking of a neurotoxic peptide containing amino acids
105–132 of the murine prion protein (MoPrP105-132) in neuroblastoma cells and primary cortical
neurons.
Results: Fluorescence microscopy and cell fractionation techniques showed that MoPrP105-132
co-localised with lipid raft markers (cholera toxin and caveolin-1) and trafficked intracellularly
within lipid rafts. This trafficking followed a non-classical endosomal pathway delivering peptide to
the Golgi and ER, avoiding classical endosomal trafficking via early endosomes to lysosomes.
Fluorescence resonance energy transfer analysis demonstrated close interactions of MoPrP105-
132 with cytoplasmic phospholipase A2 (cPLA2) and cyclo-oxygenase-1 (COX-1), enzymes
implicated in the neurotoxicity of prions. Treatment with squalestatin reduced neuronal
cholesterol levels and caused the redistribution of MoPrP105-132 out of lipid rafts. In squalestatin-
treated cells, MoPrP105-132 was rerouted away from the Golgi/ER into degradative lysosomes.
Squalestatin treatment also reduced the association between MoPrP105-132 and cPLA2/COX-1.
Conclusion: As the observed shift in peptide trafficking was accompanied by increased cell survival
these studies suggest that the neurotoxicity of this PrP peptide is dependent on trafficking to
specific organelles where it activates specific signal transduction pathways.
Background
The Transmissible Spongiform Encephalopathies (TSE)s,
otherwise known as prion diseases, are a family of neuro-
degenerative diseases that include Creutzfeldt-Jakob dis-
ease (CJD) in man, Bovine Spongiform Encephalopathy
(BSE) in cattle, and scrapie in sheep and goats. A notable
feature of these diseases is the accumulation of (PrPSc) [1],
a misfolded isoform of the host-encoded prion protein
PrPc [2,3]. Neuronal dysfunction and ultimately neuronal
death are thought to arise following deposition of fibrils
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[4-6]. However, it remains unclear if PrPSc causes neuronal
damage itself, or acts via other molecular forms of PrP that
have been suggested as causative agents in prion disease
[7-9].
The process of neuronal loss can be investigated in vitro
using highly defined synthetic peptides derived from the
protease-resistant core of PrPSc. The majority of neurotox-
icity studies have employed a peptide consisting of amino
acids 106–126 of the human prion protein (HuPrP106-
126) which possesses many of the properties of the PrPSc
isoform, notably a high β-pleated sheet content, fibril for-
mation and toxicity for neurons in vitro [7]. A correspond-
ing peptide has been identified from the murine prion
sequence (MoPrP105-132), which has also been shown to
be neurotoxic [8]. These peptides also encompass the
major part of the putative transmembrane form of PrP
(CtmPrP) that is thought to be important in prion disease
pathogenesis as transgenic mice overexpressing such PrP
molecules develop neurological disease, and the accumu-
lation of PrPres is followed closely by an increase in CtmPrP
[10,11]. In the current study we employed labelled
MoPrP105-132 to identify organelles involved in the traf-
ficking pathways of neurotoxic peptides. We demonstrate
that in neuroblastoma cells, MoPrP105-132 co-localises
with cholera toxin subunit B (CTxB), which binds to the
ganglioside GM1 [12,13] and caveolin-1 [14,15], markers
of specialised microdomains called lipid rafts.
Lipid rafts are highly enriched in cholesterol, sphingolip-
ids and a population of specific membrane proteins [16].
In some cells, lipid rafts contain cholesterol-binding pro-
teins called caveolins that define a subset of lipid raft
called caveosomes [17]. Lipid rafts also act as platforms
for cell signalling processes [18,19], suggesting that
MoPrP105-132 might interact with signalling enzymes.
As a close correlation exists between the production of
prostaglandins (PG)s and neuronal death in prion disease
[20,21], the association between MoPrP105-132 and the
enzymes PLA2 and COX responsible for the release of ara-
chidonic acid (AA) and the metabolism of AA into PGs
respectively, were studied.
There is increasing evidence that cholesterol levels within
the brain may affect the progression of some neurodegen-
erative diseases. Cholesterol depletion in vitro has been
shown to affect the integrity of lipid rafts [22,23] and
reducing cellular cholesterol levels reduces the sensitivity
of neurons to prions [23]. In the following studies we
have demonstrated that pre-treatment of neurons with
squalestatin, a drug that inhibits cholesterol production
[24], alters the surface localisation and the intracellular
trafficking of the MoPrP105-132 peptide. In addition, pre-
treatment with squalestatin significantly reduced the asso-
ciation between MoPrP105-132 and cPLA2 or COX-1.
Such observations raise the possibility that the neurotox-
icity of PrP peptides is dependent on the specific intracel-
lular trafficking pathways of such peptides and the
association with signal transduction pathways.
Results
MoPrP105-132 is located within lipid rafts
Initial studies demonstrated that to achieve internalisa-
tion and detection of labelled MoPrP105-132 in greater
than 50% of the NB4 cells required at least 30 – 90 min-
utes incubation at 37°C (data not shown). Following this
incubation period, 63% ± 8 of rhodamine-labelled
MoPrP105-132 co-localised with Alexa Fluor 488 labelled
CTxB, which binds to ganglioside-GM1 and identifies
lipid rafts [13-15] (Figure 1A). In contrast, no co-localisa-
tion between scrambled MoPrP105-132 and CTxB was
detected (Figure 1B), indicating that the localisation of
MoPrP105-132 in lipid rafts was dependent on the pri-
mary sequence of the peptide. To confirm these findings
on non-transformed cells, further experiments were con-
ducted using primary cortical neurons; comparable results
were obtained (see additional files 1A &1B). A FRET signal
generated between acceptor-conjugated MoPrP105-132
and donor conjugated CTxB indicated that the two mole-
cules were in close association, approximately 10–100 Å
(Figures 1C, 1D). In contrast, no FRET signal could be
detected between scrambled MoPrP105-132 and CTxB
(data not shown). To determine whether caveolae played
a role in the trafficking of MoPrP105-132, neuroblastoma
cells were incubated with rhodamine-labelled MoPrP105-
132 for 30 minutes, fixed and probed with FITC labelled
anti-caveolin-1. We found 73% ± 3 of MoPrP105-132 co-
localised with caveolin-1 (Fig 1E). Furthermore, a FRET
signal between MoPrP105-132 and caveolin-1 was also
detected confirming the close association of these mole-
cules (Figures 1F &1G). The fluorescence microscopy
studies were complemented by lipid rafts isolation studies
on MoPrP105-132 treated neuroblastoma cells. Follow-
ing incubation for 30 minutes, MoPrP105-132 was found
in a TfR negative, caveolin-1 and CTxB positive fraction
(Figure 1H). These results confirm that MoPrP105-132
can be found in lipid rafts and that caveolin-1 was also
present in the lipid rafts that were isolated.
MoPrP105-132 traffics via a non-classical endocytic 
pathway
The intracellular trafficking pathway of MoPrP105-132
was further investigated by incubating biotin-conjugated
MoPrP105-132 for 1 hour at 37°C before fixation. Fluo-
rescence microscopy showed that only 6% ± 3 of
MoPrP105-132 localised in TfR positive early endosomes
(Figure 2A) and only 9% ± 2 of MoPrP105-132 co-local-
ised within LAMP-1 positive lysosomes (Figure 2B). In
contrast, 77% ± 6 of scrambled MoPrP105-132 was asso-Page 2 of 12
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firming the sequence dependence of MoPrP105-132
localisation. Comparable results were obtained in pri-
mary cortical neurons (see additional files 2A, 2B). After
90 minutes at 37°C, approximately 41% ± 5 of
MoPrP105-132 co-localised with GM130, a marker for
cis-Golgi (Fig 2D) and 38% ± 4 with Grp78, which iden-
tifies the ER (Fig 2E). These findings are consistent with
previous reports that that molecules internalised in lipid
rafts traffic to the Golgi/ER [25]. The microscopy studies
were complemented by an endosomal fractionation tech-
nique, as previously described [26]. In neuroblastoma
cells incubated with MoPrP105-132 for 1 hour at 37°C,
MoPrP105-132 was detected in the whole microsomal
extract and the cell fraction known to be enriched for
Golgi and ER compartments [27], but was not found in
MoPrP105-132 is found in lipid raftsFigure 1
MoPrP105-132 is found in lipid rafts. Neuroblastoma cells incubated for 30 minutes with 30 µM rhodamine-labeled 
MoPrP105-132 and Alexa Fluor 488 labelled CTxB for 30 minutes, the nuclei were revealed using Vectashield with DAPI 
(blue). (A) Images of MoPrP105-132 (red) and CTxB (green) staining were merged using OpenLab software to show co-locali-
zation (yellow). (B) Images of scrambled MoPrP105-132 (red) and CTxB (green) staining showed that there was no co-localiza-
tion (yellow). (C) FRET analysis showing the raw data between rhodamine-labeled MoPrP105-132 and Alexa Fluor 488 labelled 
CTxB and (D), the proximity of the donor/acceptor reaction revealed by false-colour intensity. Images of neuroblastoma cells 
incubated for 30 minutes with 30 µM rhodamine-labeled MoPrP105-132 (red) and stained with FITC-labelled anti-caveolin-1 
(green), showing co-localization (yellow). (E) FRET analysis showing the raw data between rhodamine-labeled MoPrP105-132 
and FITC-labelled CTxB and (F), the proximity of the donor/acceptor reaction revealed by false-colour intensity. Scale bars, 5 
µm. (H), Western-blot analysis of triton X-100 insoluble fractions (lipid rafts) and soluble fractions (non-raft) isolated from 
neuroblastoma cells incubated with 30 µM MoPrP105-132-FITC for 30 minutes, and probed for MoPrP105-132, caveolin-1, TfR 
and GM1 (CTxB).Page 3 of 12
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2F).
Squalestatin treatment alters MoPrP105-132 trafficking
Previous studies have shown that depletion of cholesterol
in neurones protects against the neurotoxicity induced by
prion peptides [23], including MoPrP105-132 (see addi-
tional data 3). To determine whether squalestatin was
simply altering the quantity of MoPrP105-132 ingested,
squalestatin treated or untreated neuroblastoma cells
were incubated with 30 µM MoPrP105-132 conjugated to
FITC. The levels of cell associated fluorescence in each
condition was determined after 30 minutes incubation by
FACS analysis of cells and expressed as arbitrary units of
mean fluorescence intensity. There was no significant dif-
ference between the mean fluorescence intensity for
untreated and squalestatin treated cells (23.2 ± 2 com-
pared to 25.3 ± 4, n = 6, P > 0.05). As a number of studies
MoPrP105-132 avoids early endosomes and lysosomesFigure 2
MoPrP105-132 avoids early endosomes and lysosomes. Neuroblastoma incubated with biotinylated MoPrP105-132 at 
37°C, then fixed and stained with Texas Red-streptavidin (red) and TfR-FITC (green) or LAMP-1-FITC (green). Nuclei were 
revealed using Vectashield with DAPI (blue). (A) Co-localisation (yellow) was not observed between MoPrP105-132 and TfR 
or (B) between MoPrP105-132 and LAMP-1. (C) Co-localisation of biotinylated scrambled MoPrP105-132 (red) with LAMP-1 
(green) was evident. Neuroblastoma cells were incubated with biotinylated MoPrP105-132 (red) for 90 minutes, then fixed and 
stained with GM130 (green) or Grp78 (green). (D) Co-localisation was observed between MoPrP105-132 and GM130 and (E) 
between MoPrP105-132 and Grp78. Scale bars, 5 µm. (F) Separation of endosomal compartments. Neuroblastoma cells were 
pulsed with iron dextran beads, before incubation with MoPrP105-132-FITC for 1 hour. Lysosomes (F3) were extracted from 
whole microsome extracts (MEx) using a magnetic column and early endosomes (F1) and intermediate fraction (F2) isolated 
using a density gradient. Western blot analysis revealed MoPrP105-132 was present in TfR negative and LAMP-1 negative frac-
tions (F2).Page 4 of 12
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tion and trafficking are cholesterol sensitive, the effect of
squalestatin on the intracellular trafficking of MoPrP105-
132 was investigated. Following pre-treatment with squal-
estatin, neuroblastoma cells were incubated with CTxB
and MoPrP105-132 for 30 minutes at 37°C. Fluorescence
microscopy revealed that in squalestatin-treated cells only
5% ± 1 of the MoPrP105-132 co-localised with CTxB (Fig-
ure 3A), whereas 75% ± 7 of MoPrP105-132 co-localised
with CTxB in untreated neuroblastoma cells (Figure 3B).
When lipid rafts were isolated from neuroblastoma cells
that had been pre-treated with squalestatin, most of the
MoPrP105-132 was detected in the non-raft fraction,
while CTxB and caveolin-1 were present in both raft and
non-raft fractions (Figure 3C). Such findings suggest that
the localisation of MoPrP105-132 to lipid rafts is sensitive
to cholesterol depletion.
Further analysis of the trafficking of MoPrP105-132 in
squalestatin-treated neuroblastoma cells showed that
only 7% ± 2 of MoPrP105-132 co-localised with the Golgi
(Figure 4A) and 3% ± 2 of MoPrP105-132 co-localised
with the ER (Figure 4B), suggesting that in these cells
MoPrP105-132 does not undergo retrograde trafficking.
We found that 68% ± 8 of MoPrP105-132 co-localised
with early endosomes (Figure 4C) and 40% ± 6 of
MoPrP105-132 co-localised with lysosomes (Figure 4D).
These observations suggest that in squalestatin-treated
cells the MoPrP105-132 peptide is diverted away from ret-
rograde transport to the Golgi/ER and directed into the
classical endosome/lysosomal degradative pathway. A
Squalestatin reroutes MoPrP105-132 into lysosomesFigure 4
Squalestatin reroutes MoPrP105-132 into lysosomes. 
Neuroblastoma cells were incubated with 1 µM squalestatin 
for 24 hours before incubation with 30 µM MoPrP105-132-
biotin for 90 minutes, then fixed and stained with Texas Red-
streptavidin (red) and with anti-GM130, anti-Grp78, anti-
TfR-FITC or anti-LAMP-1-FITC (all green) (A) Co-localisa-
tion between MoPrP105-132 and GM130, or (B) between 
MoPrP105-132 and Grp78. (C) In squalestatin treated cells 
co-localisation was observed between MoPrP105-132 and 
TfR and (D) between MoPrP105-132 and LAMP-1. Scale bars, 
5 µm. (E) In squalestatin-treated cells, following fractionation 
of whole microsomal extracts (MEx) using iron dextran and 
density gradient centrifugation, MoPrP105-132 was detected 
in the lysosome fraction (F3).
Squalestatin reduces the distribution of MoPrP105-132 and CTxB in neu oblastoma cellsFigure 3
Squalestatin reduces the distribution of MoPrP105-
132 and CTxB in neuroblastoma cells. Neuroblastoma 
cells were incubated with 1 µM squalestatin for 24 hours and 
subsequently incubated with MoPrP105-132-rhodamine (red) 
and CTxB-Alexa Fluor 488 (green), nuclei were revealed 
using Vectashield with DAPI (blue). (A) Lack of co-localisa-
tion was apparent between MoPrP105-132 and CTxB in 
squalestatin treated cells compared with (B) untreated cells. 
Scale bar, 5 µm. (C) Isolation of lipid raft/non-raft mem-
branes from neuroblastoma cells treated with 1 µM squales-
tatin for 24 hours. In squalestatin-treated cells the majority 
of MoPrP105-132 was present in the non-raft fraction.Page 5 of 12
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MoPrP105-132 in untreated and squalestatin-treated neu-
roblastoma cells is presented as Table 1. The re-routing of
MoPrP105-132 to the classical endocytic pathway in
squalestatin-treated cells was confirmed by analysis of
endosomal fractions. In endosomal fractions isolated
from squalestatin-treated neuroblastoma cells pulsed
with MoPrP105-132 for 1 hour, MoPrP105-132 was
detected in the LAMP-1 positive, TfR negative, lysosomal
fraction (Figure 4E).
MoPrP105-132 associates with cPLA2 and COX-1
Since a close association exists between PG's and prion-
induced neurotoxicity [28-31], the relationship between
MoPrP105-13 and enzymes involved in the production of
PGs was examined. Neuroblastoma cells were incubated
with MoPrP105-132 for either 5 minutes or 20 minutes at
37°C, fixed, and stained with antibodies to either cPLA2
or COX-1. After 5 minutes 38% ± 7 of MoPrP105-132 co-
localised with cPLA2 (Figure 5A) and 70% ± 5 of
MoPrP105-132 co-localised with COX-1 (Figure 5C).
After 20 minutes only 2% ± 1 of MoPrP105-132 co-local-
ised with cPLA2 (Figure 5B) and no co-localisation was
observed between MoPrP105-132 and COX-1 (Figure
5D), indicating that the association between MoPrP105-
132 and cPLA2 or COX-1 was short lived.
Squalestatin treatment reduces the association between 
MoPrP105-132 and cPLA2/COX-1
Since treatment with squalestatin protected neurons
against prions [23] the effects of squalestatin on the co-
localisation between MoPrP105-132 and cPLA2 was
examined 5 minutes after the addition of peptide. Pre-
treatment with 1 µM squalestatin significantly reduced the
association between MoPrP105-132 and cPLA2 (13% ± 4
compared with 38% ± 7 in untreated cells) (Figure 6A).
Similarly, pre-treatment with squalestatin reduced the
association between MoPrP105-132 and COX-1 (5% ± 5
compared to 70% ± 5 in untreated cells) (Figure 6B). Neu-
rons treated with PAF antagonists are also resistant to the
otherwise toxic effects of prions [23] and pre-treatment
with 2 µM of a PAF antagonist (Hexa-PAF) reduced the
association between MoPrP105-132 and cPLA2 (22% ± 6
v 38% ± 7 in untreated cells) (Figure 6C). Treatment with
Hexa-PAF also reduced the association between
MoPrP105-132 and COX-1 (13% ± 3 compared to 70% ±
5 in untreated cells) (Figure 6D). A summary of the differ-
ences in co-localisation between MoPrP105-132 and the
signalling enzymes in untreated and squalestatin-treated
neuroblastoma cells is presented as Table 2.
Discussion
Although neuronal dysfunction and ultimately neuronal
loss are key features of prion diseases, the molecular
mechanisms that that result in neuronal damage remain
poorly understood. Synthetic peptides have been exten-
sively used to model the process of neuronal degeneration
in vitro and in the present study we analysed the trafficking
of MoPrP105-132 in neuroblastoma cells and primary
MoPrP105-132 associates with cPLA2 and COX-1Figure 5
MoPrP105-132 associates with cPLA2 and COX-1. 
Neuroblastoma cells were incubated with 30 µM MoPrP105-
132-biotin for 5 minutes or 20 minutes at 37°C then fixed 
and stained with Texas Red-streptavidin (red), anti-cPLA2-
FITC (green) or anti-COX-1-FITC (green). Nuclei were 
revealed using Vectashield with DAPI (blue). (A) Co-localisa-
tion (yellow) between MoPrP105-132 (red) and cPLA2 
(green) after 5 minutes, but not after 20 minutes (B). (C) Co-
localisation (yellow) between MoPrP105-132 (red) and anti-
COX-1-FITC (green) after 5 minutes, but not after 20 min-
utes (D). Scale bars, 5 µm.
Table 1: Squalestatin alters the trafficking of MoPrP105-132 in 
neuroblastoma cells. The percentage of MoPrP105-132 that co-
localised with cellular markers as shown in untreated 
neuroblastoma cells and cells treated for 24 hours with 1 µM 
squalestatin. Values shown are mean percent of peptide that co-
localises with markers as shown, ± SD, which was calculated 
after counting a minimum of 3 cells.
% Co-localisation with MoPrP105-132
Untreated Squalestatin-treated
CTxB 63% ± 8 5% ± 1
Caveolin-1 73% ± 3 9% ± 3
GM130 41% ± 5 7% ± 2
Grp 78 38% ± 4 3% ± 2
TfR 6% ± 3 68% ± 8
LAMP-1 9% ± 2 40% ± 6Page 6 of 12
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co-localised with ganglioside GM1, a marker of lipid rafts
identified by CTxB, and with caveolin-1, a marker of a
lipid raft subset called caveolae. FRET analysis, a tech-
nique with spatial resolution beyond the limits of conven-
tional fluorescence imaging, demonstrated that
MoPrP105-132 was intimately associated with both GM1
and caveolin-1 (minimal spacing of 10–100 Å required to
observe FRET signals). Separation of lipid rafts from cell
membranes by detergent extraction confirmed the micro-
scopy data (MoPrP105-132 was detected only in the GM1
and caveolin-1 positive fraction). It not clear why
MoPrP105-132 localises to lipid rafts, one possibility is
that lipid rafts contain a high percentage of saturated fatty
acids, which provides a hydrophobic environment that
stabilises the peptide within the membrane. Another pos-
sibility is that many of the putative receptors for prions
[32] are found within lipid rafts, thus, peptide-receptor
interactions may be responsible for targeting MoPrP105-
132 to these domains.
The trafficking of molecules within cells is partly depend-
ent on the mechanism of internalisation, thus, molecules
that are ingested via clathrin-dependent endocytosis traf-
fic via endosomes into degradative lysosomes [33]. In
contrast, agents targeted to lipid rafts or caveolae are inter-
nalised by clathrin-independent endocytosis and traffic
into different cellular compartments. MoPrP105-132 traf-
ficked into both the Golgi and ER (co-localised with the
markers GM130 and Grp78); consistent with reports that
the cargo of caveolae is directed into the Golgi [14,15,34].
These results are consistent with MoPrP105-132 traffick-
ing via the non-classical endocytic pathway, recently
defined through the trafficking of GM1 positive lipid rafts
[12]. Only a small percentage of MoPrP105-132 was asso-
ciated with either TfR or LAMP-1, indicating that it was
rarely found in early endosomes or lysosomes. Micros-
copy data was supported by organelle fractionation stud-
ies in which endosomes involved in the classical
endocytic pathways were fractionated. MoPrP105-132
was not found in fractions containing either TfR or LAMP-
1, but was found in an intermediate density fraction
known to contain Golgi/ER [27]. Taken together these
results indicate that MoPrP105-132 does not traffic down
the classical endocytic route and avoids the lysosomes. We
speculate that the avoidance of proteolytic lysosomes may
facilitate the build up of neurotoxic peptides during dis-
ease progression. The localisation of MoPrP105-132 to
lipid rafts depends on the sequence of amino acids as a
control peptide made up of the same amino acids synthe-
sized in a scrambled sequence did not localise within lipid
rafts. Subsequently, the scrambled MoPrP105-132 control
peptide trafficked to endosomes and lysosomes, empha-
sising the sequence dependent nature of the intracellular
trafficking of the peptide. Although most of the studies
presented are on neuroblastoma cells we found that
MoPrP105-132 trafficked in a similar manner in non-
transformed primary cortical neurones. The sequence spe-
cificity of this effect would argue against MoPrP non-spe-
Table 2: Squalestatin reduces co-localisation between 
MoPrP105-132 and cPLA2/COX-1. The percentage of MoPrP105-
132 that co-localised with the signalling enzymes cPLA2 or COX-
1 in untreated neuroblastoma cells and cells treated for 24 hours 
with either 1 µM squalestatin or 2 Hexa-PAF, 5 minutes after the 
addition of peptide. Values shown are mean ± SD, calculated 
after counting a minimum of 3 cells.
Co-localisation with 
MoPrP105-132
Drug Treatments
Untreated Squalestatin Hexa-PAF
cPLA2 38% ± 7 13% ± 4 22% ± 6
COX-1 70% ± 5 5% ± 5 13% ± 3
Squalestatin reduces the association between MoPrP105-132 and cPLA2 and COX-1Figure 6
Squalestatin reduces the association between 
MoPrP105-132 and cPLA2 and COX-1. Neuroblastoma 
cells were pre-treated with either 1 µM squalestatin or 2 µM 
Hexa-PAF prior to incubation with 30 µM MoPrP105-132-
biotin for 5 minutes at 37°C, fixed and stained with Texas 
Red-streptavidin (red) anti-cPLA2-FITC or anti-COX-1-FITC 
(green). Nuclei were revealed using Vectashield with DAPI 
(blue). Images show the extent of co-localisation (yellow) 
between MoPrP105-132 (red) and cPLA2 (green) (A) or 
between MoPrP105-132 (red) and COX-1 (green) (B) in 
squalestatin-treated cells. Similarly, images show the extent 
of co-localisation (yellow) between MoPrP105-132 (red) and 
cPLA2 (green) (C) or between MoPrP105-132 (red) and 
COX-1 (green) (D) in Hexa-PAF-treated cells. Scale bars, 5 
µm.Page 7 of 12
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hydrophobicity, as the composition of the scrambled pep-
tide was the same as MoPrP105-132.
Previous studies demonstrated that neurons treated with
the cholesterol synthesis inhibitor squalestatin, a drug
that inhibits squalene synthase and reduces cholesterol
production without affecting the production of isopre-
noid precursors [24], were protected against the otherwise
toxic effects of prions [23]. Since the formation of lipid
rafts and lipid raft-dependent uptake is sensitive to choles-
terol depletion [35], we examined the effects of squalesta-
tin-treatment on the trafficking of MoPrP105-132. One
possible explanation for the neuroprotective effects of
squalestatin, that it prevents ingestion of MoPrP105-132,
was excluded by studies that showed that there was no sig-
nificant difference in the amounts of peptide taken up by
untreated and treated cells. However, we did detect a dif-
ference in the trafficking of MoPrP105-132 between
treated and untreated cells. Squalestatin-treatment of neu-
roblastoma cells greatly reduced the amounts of
MoPrP105-132 that co-localised with either CTxB or with
caveolin-1 indicating the most of the peptide was no
longer present in lipid rafts. This observation was con-
firmed by Triton X-100 extractions which showed that
most of the MoPrP105-132 peptide was now in the non-
raft fraction. Fluorescence microscopy and cell fractiona-
tion studies both suggested that in squalestatin-treated
cells MoPrP105-132 trafficked down a classical endocytic
pathway into lysosomes, avoiding the Golgi/ER. These
results are consistent with reports that cholesterol deple-
tion results in the loss of lipid raft functions, including
raft-dependent endocytosis and subsequent intracellular
trafficking [36].
The neurotoxicity of prion-derived peptides depends on
the activation of specific signalling pathways including
PLA2 and the COX enzymes that convert AA into PGs [28-
31]. Furthermore, prion-induced injury is associated with
increased levels of PGE2 [20,21]. Selective inhibitors indi-
cated the importance of the COX-1 isoform in prion-
mediated neurotoxicity [28]. In untreated neuroblastoma
cells a significant proportion of MoPrP105-132 co-local-
ised with cPLA2 and COX-1, this association was short
lived (seen at 5 minutes after the addition of peptide but
not after 20 minutes). The brief association observed
could be a result of peptide rapidly transiting the COX-1/
cPLA2 containing compartment, or alternatively localisa-
tion of these enzymes is known to be transient and
dependent on the activation state of the cell [37]. These
observations suggest that the association of MoPrP105-
132 with cPLA2 and COX-1 activates these enzymes lead-
ing to the production of toxic second messengers. Pre-
treatment of neuroblastoma cells with squalestatin
reduced the co-localisation between MoPrP105-132 and
cPLA2 or COX-1, and reduced prion-induced PGE2 pro-
duction [23]. Taken together these observations suggest
that in normal neuroblastoma cells MoPrP105-132 accu-
mulates in lipid rafts where they activate the PLA2/COX
pathway resulting in the production of neurotoxins
including PGE2 [28]. Thus, the neuroprotective effect of
squalestatin treatment may simply be by the dispersal of
lipid rafts, which prevent the formation of MoPrP105-
132/PLA2/COX-1 complexes and reduce the production
of neurotoxins. Similar effects where found in neuroblas-
toma cells treated with the PAF antagonist (Hexa-PAF),
which protects neurones against prion-mediated neuro-
nal damage [30]. Pre-treatment of neuroblastoma cells
with the PAF antagonist reduced the co-localisation
between MoPrP105-132 and cPLA2, and significantly
between MoPrP105-132 and COX-1. This observation is
consistent with reports that PAF antagonists reduce PGE2
production in prion peptide treated neuroblastoma cells
[38].
Conclusion
In conclusion, our data demonstrate that in normal neu-
roblastoma cells the majority of MoPrP105-132 is found
in lipid rafts and traffics via a non-classical endocytic,
recycling pathway. This pathway involves internalisation
via lipid rafts and trafficking into the Golgi and ER. Dur-
ing this process MoPrP105-132 co-localises with the sig-
nalling enzymes, cPLA2 and COX-1, enzymes that are
involved in the production of prostaglandins, bioactive
lipids closely associated with neuronal death in prion dis-
eases. Treatment of neuroblastoma cells with squalestatin
was shown to prevent peptide-induced neurotoxicity but
did not prevent internalisation. However squalestatin
treatment was associated with altered localisation and
trafficking of MoPrP105-132 in neuroblastoma cells. In
these cells MoPrP105-132 is not found in lipid rafts, did
not associate with cPLA2 and COX-1, and trafficked into
lysosomes. We speculate that the effect of squalestatin in
negating prion peptide induced neurotoxicity may result
from altered trafficking of MoPrP105-132 thus preventing
interactions with specific signalling pathways. This
hypothesis is strengthened by the observation that a sec-
ond neuroprotective drug, Hexa-PAF, also prevented pep-
tide association with cPLA2 and COX-1. As altering the
trafficking of prion-derived peptides appears to be associ-
ated with protection against neurotoxicity, strategies to
manipulate intracellular trafficking pathways could lead
to novel therapeutic approaches in prion disease.
Methods
Cell Lines
The murine neuroblastoma NB4-1A3 cell line (European
Collection of Cell Cultures) was maintained in RPMI-
1640 (Invitrogen, Paisley, UK) supplemented with 2 mM
glutamine and 5% foetal calf serum (FCS). Cells were dis-Page 8 of 12
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with poly-D-lysine (50 µg/ml) at 3 × 105 cells per well (24
well plates) and left to adhere overnight before further
use.
Primary neuronal cultures
Primary cortical neurons were prepared from embryonic
day 15.5 mice as previously described [39] and plated
onto sterilised 13 mm glass coverslips pre-coated with
poly-D-lysine (50 µg/ml) at 2 × 106 cells per well (24 well
plates) [39]. After 2 hours, media was changed to neuro-
basal medium (NBM) containing B27 components (Invit-
rogen), 2 mM glutamine and 5 µM cytosine arabinoside
(Sigma, Dorset, UK) to prevent the proliferation of astro-
glia. Neuronal cultures were used 7 days after plating.
PrP Peptides
Synthetic PrP peptides were derived from the sequence of
murine prion protein (MoPrP105-132; KTNLKHVA-
GAAAAGAVVGGLGGYMLGSA) [8] as was a control pep-
tide containing the same amino acids in a scrambled
order (scrambled MoPrP105-132; NGAGKAGMVGLYG-
AHGATAKVSLVGALA). Peptides were synthesized by
solid-phase chemistry and purified by reverse-phase
HPLC (gift from Dr. J. Langeveld, ID-Lelystad/Pepscan
Systems, The Netherlands). To enable detection of the
peptides, they were labelled with rhodamine, fluorescein
or biotin.
Fluorescence microscopy
NB4 1A3 neuroblastoma cells were incubated with 30 µM
rhodamine or biotinylated MoPrP105-132 or scrambled
peptide conjugated to rhodamine or biotin for 20 to 90
minutes at 37°C. Biotinylated MoPrP105-132 was
detected using streptavidin Texas Red (Vector Laborato-
ries, Peterborough, UK). Lipid rafts were identified using
1 µg/ml CTxB conjugated to Alexa Fluor 488 (Molecular
Probes, The Netherlands) for 30 minutes at 37°C. FITC-
dextran (70 kDa; Molecular Probes) was used as a marker
for fluid-phase uptake. For intracellular staining, cells
were fixed with 1% paraformaldehyde, Following incuba-
tion, cells attached to coverslips were washed once in PBS
and fixed in 1% paraformaldehyde. Lipid rafts were iden-
tified using 1 µg/ml CTxB conjugated to Alexa Fluor 488
(Molecular Probes, The Netherlands) for 30 minutes at
37°C. For intracellular staining, cells were permeabilised
(PBS containing 2% FCS, 2 mM EDTA, 0.1% w/v saponin)
and incubated in blocking buffer (PBS containing 1%
FCS) to prevent non-specific binding. Biotinylated
MoPrP105-132 was detected using streptavidin Texas Red
(Vector Laboratories, Peterborough, UK). Early endo-
somes and lysosomes were stained using antibodies spe-
cific for the transferrin receptor (TfR-FITC; BD
Pharmingen, Oxford, UK) and lysosomal associated
membrane protein-1 (LAMP-1-FITC; BD Pharmingen)
respectively. The Golgi was stained using GM130 (Santa
Cruz Biotechnology, CA, USA), a marker for the Golgi,
and visualised using anti-rabbit FITC (Vector Laborato-
ries). In addition, the ER was stained using anti-Grp78
(Stressgen Biotechnology, San Diego, USA) and visualised
using anti-rabbit FITC (Vector Laboratories). Anti-COX-1-
FITC (BD Biosciences) and anti-cPLA2-FITC (Santa Cruz
Biotechnology, California, USA) were used for investigat-
ing signalling enzymes. Vectashieid containing DAPI
(Vector Laboratories) was used to stain cell nuclei. Cover-
slips were mounted onto glass slides (Speci-Microsystems
Ltd, Surrey, UK) and fluorescence microscopy was per-
formed with an Axiovert S-100 Zeiss microscope using a
63× oil immersion lens. Serial images in z were captured
using a Hamamatsu Orca LCD camera and unprocessed
images (additional file 4) were deconvolved using Open-
Lab software (Improvision, Coventry, UK). Images shown
are representative of at least 10 fields of view, with a cell
density of typically 5 – 10 cells per field. The degree of co-
localisation in fluorescent deconvolved images was evalu-
ated from the number of co-localised pixels within a given
cell for a minimum of 3 representative cells, as deter-
mined by OpenLab software. For drug treatment, cells
were pre-treated under the following conditions prior to
the addition of prion peptides: 1 µM squalestatin (Glaxo-
SmithKline, Herts, UK) or 2 µM 1-O-alkyl-2-acetyl-sn-
glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine
(Hexa-PAF) (Novabiochem, Nottingham, UK) overnight
at 37°C before use.
FRET
NB4 1A3 cells were incubated with 30 µM MoPrP105-132
conjugated to rhodamine and either CTxB conjugated to
Alexa Fluor 488, or FITC-labelled caveolin-1 for 30 min-
utes at 37°C. Fluorescence microscopy was performed
with an Olympus BX50 fluorescence microscope
equipped with appropriate excitation and emission filter
sets. Images representing donor fluorescence, acceptor flu-
orescence (rhodamine) and FRET signal were taken.
Donor and acceptor bleed through values were calculated
and the FRET signal quantified and FRET images gener-
ated using OpenLab FRET module software [40].
Lipid raft isolation
Lipid raft isolation was performed as previously described
[41]. Briefly, NB4 1A3 cells were incubated with 30 µM
MoPrP105-132-FITC for 30 minutes, before being lysed
with distilled H2O and centrifuged (10 minutes at 1,000 ×
g). Pellets were suspended in 1% Triton-X 100 in PBS plus
5 mM phenylmethyl sulfonyl fluoride (PMSF) and incu-
bated for 30 minutes on ice. After centrifugation (10 min-
utes at 14,000 × g), the supernatant was kept as the non-
lipid raft fraction. Pellets were suspended in extraction
buffer (10 mM Tris-HCL, 10 mM NaCl, 10 mM EDTA,
0.5% Nonidet P-40 and 0.5% Sodium Deoxycholate) andPage 9 of 12
(page number not for citation purposes)
BMC Neuroscience 2007, 8:99 http://www.biomedcentral.com/1471-2202/8/99centrifuged (10 minutes at 14,000 × g). The supernatant
obtained contained the lipid raft fraction. Using western
blot analysis, fractions were transferred onto nitrocellu-
lose and probed for MoPrP105-132 using anti-FITC
horseradish peroxidase (HRP;Molecular Probes). Frac-
tions were probed using anti-TfR-FITC and anti-Caveolin-
1-FITC (Santa Cruz Biotechnology) and detected using
anti-FITC HRP. Fractions were visualised using enhanced
chemiluminescence (ECL). Using slot blot analysis, gan-
glioside-1 (GM1) was detected using CTxB-FITC (Sigma)
followed by anti-FITC HRP. For drug treatment, NB4 1A3
cells were pre-treated with squalestatin as described
above.
Cell homogenisation and fractionation
NBA 1A3 cells were fractionated using a combination of
magnetic isolation of lysosomes [26] and gradient centrif-
ugation [42,43]. Cells were incubated with iron dextran,
produced from 40 kDa dextran as previously described
[44] for 1 hour at 37°C. Media containing iron dextran
was removed and replaced with fresh medium and incu-
bated overnight. After incubation with 30 µM MoPrP105-
132-FITC for 1 hour at 37°C, NB4 1A3 cells were scraped
into cold (4°C) homogenisation buffer (0.5 mM EGTA,
0.5 mM EDTA, 20 mM HEPES, 0.05% gelatin and 250
mM sucrose). Cells were centrifuged (250 × g for 8 min-
utes) and suspended in 1 ml homogenisation buffer and
then lysed by repeat passage through a 25 G syringe.
Nuclei and large fragments were removed by low speed
centrifugation (110 × g for 6 minutes) and the resultant
supernatant was then applied to a MACS column
(Miltenyi Biotec, Surrey, UK) and allowed to run through
the column by gravity to give a non-lysosomal fraction.
The column was then washed with homogenisation
buffer before being removed from the magnet and the
remaining homogenate was eluted, giving a lysosomal
fraction [F3]. Using a density gradient technique [26], the
non-lysosomal fraction was layered on top of a two step
17% (w/w) Percoll (Amersham Biosciences, UK), 64%
(w/w) sucrose cushion. After ultracentrifugation (1 hour
at 80,000 × g) using a Beckman Type 70Ti fixed angle
rotor, bands containing endosomal organelles [F1] and
Golgi and ER [F2] were removed and concentrated by cen-
trifugation (100,000 × g for 30 minutes). The protein con-
tent of these fractions were standardised following protein
assay (Pierce MicroBCA kit; Pierce, Cheshire, UK). Gel
electrophoresis of the endosomal fractions was performed
using precast 4–12% Bis-Tris gradient gels with 2-(N-mor-
pholino)ethanesulfonate (MES) running buffer
(NuPAGE; Invitrogen) and proteins were transferred onto
nitrocellulose, using western blot analysis and probed for
MoPrP105-132 using anti-FITC HRP. Secondary antibody
anti-FITC HRP was used to detect TfR-FITC and LAMP-1-
FITC and fractions were visualised using enhanced chemi-
luminescence ECL. For drug treatment, NB4 1A3 cells
were pre-treated with squalestatin as described above.
Flow Cytometry
NB4 1A3 cells were incubated with FITC-conjugated
MoPrP105-132 for 30 minutes at 37°C. Cells were then
centrifuged and fixed with 1% paraformaldehyde for 10
minutes, washed and suspended in FACS flow (BD,
Pharmingen). Cell associated fluorescence was deter-
mined by FACS analysis (FACSCalibur; Becton Dickin-
son), and expressed as arbitrary fluorescence units (mean
fluorescence intensity) using Cell Quest software. Flow
cytometry was also performed on MoPrP105-132-FITC
treated, NB4 1A3 cells that had been pre-treated with
either squalestatin as described above.
Statistical Analysis
Treatment effects were compared using one and two way
analysis of variance techniques as appropriate. For all sta-
tistical tests, significance was set at the 1% level. Percent-
age co-localisation in fluorescent deconvolved images was
determined by counting the number of co-localised pixels
against the number of pixels that did not co-localise, using
OpenLab software. Percentage of co-localisation was pre-
sented as% ± standard deviation (SD), which was calcu-
lated after counting a minimum of 3 cells.
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